Abstract:Copyright: © 2013 Qiu L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited In the latest several decades, we have witnessed the striking development of synthetic polymers as drug carriers from the early issue as implant agents to update various nano-scaled drug delivery systems via transmucosal, oral or intravenous administration. Of these, polymeric nanoparticles delivering anti-cancer drugs, biomacromolecular antibody or genetic substance such as DNA or siRNA to tumor have received predominant attention. In these delivery systems, the polymers play important roles to improve the solubility, regulate the biodistribution, prolong the half-life and control the release of drug, consequently enhanced therapy efficacy and minimized side effect has been expected. By now, quite many polymers have been explored and it has been found that different pharmaceutical formulations would lead to different results. Therefore, the rational design of polymer and formulation, and then the proper combination of both of them is the prerequisite to fabricate a successful drug delivery system. The major method to design optimal polymer can be classified to top-down and bottom-up methods [1]. Bottomup design methods prepare the polymer derivations on the basis of chemical properties of polymers, while top-down design method is adopted to modify the polymer considering the requirement of cancer therapy. Using bottom-up method, it is easier for chemists to acquire a large quantity of novel polymers, but most of them finally fail to meet the demand of clinical application. On the contrary, top-down method directly aims to clinical application of polymers and the corresponding formulation. With this idea, how to synthesize objective polymer is always the difficulty for those researches working in clinic. Obviously, merging these two methods together is an ideal method to facilitate the development of functional polymers and their transfer from the lab to practical application. Herein, I focus on amphiphilic polymer design for cancer therapy.

Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy

Polymeric Prodrug by Supramolecular Polymerization

Polymer-Based Prodrugs For Cancer Chemotherapy

Polymer-Based Drug Delivery Systems for Cancer Therapeutics

Supramolecular polymeric prodrug micelles for efficient anticancer drug delivery

Polymer-drug conjugates as nanomedicine: a review

Polyprodrug Nanomedicines: an Emerging Paradigm for Cancer Therapy

Polymer-Drug Conjugates: Novel Carriers for Cancer Chemotherapy

Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy

Polymer Conjugate as the New Promising Drug Delivery System for Combination Therapy against Cancer

Polymeric Prodrugs Containing Metal-Based Anticancer Drugs

Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy

Rational Design of Synthetic Polymers As Drug Carriers for Cancer Therapy

Targeted Delivery of Anticancer Therapeutics with Polymers by Harnessing Tumor Microenvironment Acidity

100Th Anniversary of Macromolecular Science Viewpoint: Biological Stimuli-Sensitive Polymer Prodrugs and Nanoparticles for Tumor-Specific Drug Delivery

Alleviation of Tumor Invasion by the Development of Natural Polymerbased Low-risk Chemotherapeutic Systems - review on the Malignant Carcinoma Treatments

Polymer-based nanoparticles in targeted cancer therapy: a review

Prodrugs for Improving Tumor Targetability and Efficiency.

Stimuli-responsive Polyprodrug for Cancer Therapy

Biopolymeric nanocarriers in cancer therapy: unleashing the potency of bioactive anticancer compounds for enhancing drug delivery

Tumor microenvironment-responsive self-assembling polymeric prodrug-based nanomaterials for cancer therapy